Toft Group Completes Executive Search for Vice President, Business Development for Inivata in Research Triangle Park, NC

Executive search firm Toft Group has placed Thomas Schlumpberger, PhD, as Vice President of Business Development for Inivata in Research Triangle Park, NC.

Dr. Schlumpberger was previously Head of Diagnostic Business and Vice President, Diagnostics with Singulex. Prior to that, he held leadership positions at Annai Systems and AliveCor. Dr. Schlumpberger served as the Chief Commercial Officer at Invitae (f/k/a Locus Development). Earlier in his industry career, Thomas served with Epocal as Senior Vice President of International Sales and Business Development. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX.

Dr. Schlumpberger holds a PhD in Molecular and Cell Biology from the University of California, Berkeley, and an MS in Electrical Engineering and Information Theory from the Technical University, Munich, Germany.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Inivata

Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK.

Toft Group Completes Search for Associate Director, Human Resources for Puma Biotechnology, Inc. (NASDAQ: PBYI), in Los Angeles, CA

Executive search firm Toft Group has placed Laci Mayton as Associate Director of Human Resources at Puma Biotechnology, Inc. in Los Angeles, CA.

Ms. Mayton was previously the Human Resource Manager for GenMark Diagnostics. Prior to that, Ms. Mayton was with Thermo Fisher Scientific as Human Resources Manager. Ms. Mayton is a certified human resources professional with a Six Sigma Black Belt. She holds a degree in political science from Sam Houston State University in Texas.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Toft Group Completes Search for Senior Vice President, Commercial Operations for Novoheart (TSXV: NVH; FWB: 3NH)

Executive search firm Toft Group has placed Bill Williams, PhD as Senior Vice President, Commercial Operations for Novoheart (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company.

Dr. Williams has over 20 years of experience in the life science industry spanning business development, sales and marketing. He was most recently Vice President, Global Sales, Marketing and Business Development with Organovo, Inc. He joined Organovo from Aushon Biosystems where he spent 3 years as their Vice President, Global Sales and Marketing. Earlier in his industry career, Dr. Williams held management roles for Ciphergen Biosystems and Beckman Coulter.

Dr. Williams holds a PhD in Analytical Chemistry from Texas A&M University.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Novoheart

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.  Also known as ‘human heart-in-a-jar’, Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.

Toft Group Completes Search for Vice President, Global Customer Operations for Luminex Corporation (Nasdaq:LMNX) in Austin, TX

Executive search firm Toft Group has placed W. Ryan Snellings as Vice President of Global Customer Operations for Luminex Corporation (Nasdaq:LMNX) in Austin, TX.

Mr. Snellings was most recently the Vice President of Operations at Fresenius Kabi, a leading global health care company. He has over 15 years’ experience in service operations and logistics and spent several years working in Europe leading the service team that supports Europe, Middle East, and Africa. Earlier in his industry career, Mr. Snellings served with Baxter Healthcare. Mr. Snellings holds an MBA from the Keller Graduate School of Management and a BS in Information Studies from Florida State University.

About Luminex Corporation

Luminex Corporation offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Manager of Medical Affairs for QOL Medical, LLC. in Vero Beach, FL

Executive search firm Toft Group has placed Lauren Remkus, PharmD, as Manager of Medical Affairs for QOL Medical, LLC. in Vero Beach, FL.

Dr. Remkus was previously Senior Medical Science Liaison at Shire Pharmaceuticals. She joined Shire in May 2013 as Manager, Medical Communications, Global Medical Affairs. Dr. Remkus also served as a Fellow at Janssen Research and Development with responsibility for safety evaluations including review of clinical and post – marketing adverse event case reports. She also authored post-marketing safety documents including periodic safety update report (PSUR) and ad hoc reports written to identify potential adverse drug reactions.
Dr. Remkus holds a PharmD from Touro College of Pharmacy in New York.

About QOL Medical

QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan products in underserved markets. QOL Medical ensures an expanded clinical awareness and patient access for improved quality of life in the treatment of rare and orphan diseases. The Company currently markets two FDA-approved products: Sucraid® (sacrosidase) Oral Solution and Ethamolin® (Ethanolamine Oleate) Injection, 5%.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Vice President, Marketing for Exact Sciences Corp. (Nasdaq: EXAS) in Madison, WI

 

Executive search firm Toft Group has placed Kristen Weiler as Vice President of Marketing with Exact Sciences (Nasdaq: EXAS) in Madison, Wisconsin.

Ms. Weiler has held multiple roles in marketing across a broad range of therapeutic franchises. Her most recent position was as Senior Marketing Director of the Rheumatology portfolio at AbbVie, leading the brand performance of HUMIRA. Earlier in her industry career she led commercial development for ABT-874, anti-IL-12/23 antibody for psoriasis and Crohn’s disease and brand marketing for HUMIRA PsA indication in dermatology while also leading commercial development activities for future psoriasis indication. Ms. Weiler is actively involved in the Crohn’s and Colitis Foundation of America (CCFA) through fundraising and encouraging pediatric drug development.

Ms. Weiler holds a BS in Business Administration/Operations Management from the University of Wisconsin.

About Exact Sciences, Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Senior Medical Director for Leap Therapeutics (NASDAQ: LPTX) in Cambridge, MA

Executive search firm Toft Group has placed Girish Naik, MD, MBA as Senior Medical Director with Leap Therapeutics in Cambridge, MA.

Dr. Naik was previously a clinical researcher at Dana-Farber Cancer Institute. Before this appointment, Dr. Naik was Associate Scientific Manager/Medical Lead – Clinical Development at Biocon Research Ltd. where he was a physician-lead for novel biologics in oncology/immunology. Dr. Naik also served as PG Registrar (Pharmacology and Clinical Pharmacology) at Christian Medical College. He got his start in the medical industry as a surgeon at the M S Ramaiah Medical Teaching and Memorial Hospitals.

Dr. Naik holds an MD in Pharmacology from Christian Medical College in Vellore, India; an MBA from Sikkim Manipal University; and a diploma of advanced studies in pharmaceutical medicine from the University of Basel, Switzerland.

About Leap Therapeutics

Leap Therapeutics (NASDAQ:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers, with an emerging focus on patients with defined mutations of the Wnt pathway and in combination with immune checkpoint inhibitors. Leap’s second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response that is in two advanced solid tumor studies.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

 

Toft Group Completes Search for Vice President of Global Clinical Sciences for Greenwich Biosciences in Carlsbad, CA

Executive search firm Toft Group has placed Eduardo Dunayevich, MD, Vice-President of Global Clinical Sciences with Greenwich Biosciences in Carlsbad, CA.

Dr. Dunayevich is a board-certified psychiatrist with clinical development expertise within biotechnology and pharmaceutical companies. He recently served as Chief Medical Officer with Annexon Biosciences, with responsibility for clinical development, clinical operations and regulatory affairs across their neuroinflammation and intraocular therapy programs.

Previously, he held the role of Vice President and Global Product Lead, CNS at Takeda Pharmaceuticals. Prior to joining Takeda, Dr. Dunayevich was Executive Director and Global Development Leader, Neuroscience for Amgen. Dr. Dunayevich also spent 5 years with Orexigen Therapeutics as their Chief Medical Officer. Before that, he worked with Eli Lilly as a Medical Advisor in the Clinical Neuroscience Program Phase. Earlier in his industry career, Dr. Dunayevich served as Director of the Clinical Psychobiology Program, Psychobiology Inpatient Unit and Division of Clinical Trials of the Psychotic Disorders Research Program at the University of Cincinnati.
Dr. Dunayevich holds an MD from the University of Buenos Aires Medical School, Argentina.

About GW Pharmaceuticals plc and Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, pending DEA rescheduling. The Company has submitted a regulatory application in Europe for the adjunctive treatment of LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms (IS). GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Chief Technology Officer for ImpediMed Ltd. in Carlsbad, CA

Executive search firm Toft Group has placed Mr. Sashi Tripathi as Chief Technology Officer at ImpediMed Ltd. (ASX: IPD), in ImpediMed’s US office in Carlsbad, CA.

Mr. Tripathi is an accomplished healthcare technology leader. As the SVP of Technology & Operations of New Century Health, he oversaw all aspects of IT, project and product management, product development and operations. He joined New Century Health from Springfield Clinic where he was the Chief Information Officer responsible for strategy, development, management and integration of the organization. Previously, Mr. Tripathi was the VP of IT for Facey Medical.

Earlier in his industry career, Mr. Tripathi served as a Product Development Consultant for Agnity Healthcare and as Global IT Director for St. Jude Medical. Mr. Tripathi holds an MS in Industrial Engineering & Operations Research from the Indian Institute of Technology and a BE in Mechanical Engineering from M.M.M. Engineering College.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About ImpediMed, Ltd.

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

Toft Group Completes Search for Vice President, Information Technology for Synthetic Genomics, Inc. (SGI), in La Jolla, CA

Executive search firm Toft Group has placed Timothy E. Cooley as Vice President, Information Technology at Synthetic Genomics, Inc. (SGI), in La Jolla, CA.

Mr. Cooley has many years of experience in leading information technology in life sciences companies. He has previously served as Director of Business Solutions for MPI Research, Executive Vice President of US Operations at Molecular Health, and CIO for NAMSA. He also volunteers as Chief Data Officer for the Human Health Project. Earlier in his industry career Mr. Cooley spent 15 years with Eli Lilly where he held several roles, most recently as their Director of Information Technology, Medical and Health Outcomes.  Mr. Cooley holds a BS in Microbiology from Texas A&M University

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Synthetic Genomics, Inc.

Synthetic Genomics, Inc. (SGI) is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With an unmatched understanding of how DNA and RNA instruct the functions of life, we program cells for improved purpose and function. Our R&D competencies focus on our novel self-amplifying RNA replicon platform for infectious disease and oncology vaccines and therapeutics and our algal cell systems for industrial and biotherapeutic discovery and manufacturing. Built on a legacy of scientific firsts, our team of biological engineers are shaping the future bioeconomy.